Association between serum lipids and membrane fatty acids and clinical characteristics in patients with schizophrenia

Acta Psychiatrica Scandinavica

Volumn 132, Issue 4, 2015, Pages 293-300

  Solberg, D K ^a,b   Bentsen, H ^b   Refsum, H ^b   Andreassen, O A ^c,d  

^a Institute for Military Psychiatry   (Norway)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Dyslipidemia; Membrane lipids; Schizophrenia; Symptom levels

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; FATTY ACID; MEMBRANE LIPID;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; MIDDLE AGED; PSYCHOLOGY; SOCIAL CLASS; STATISTICAL MODEL;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FATTY ACIDS; FEMALE; HUMANS; LINEAR MODELS; MALE; MEMBRANE LIPIDS; MIDDLE AGED; SCHIZOPHRENIA; SOCIAL CLASS;

EID: 84941731303     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12388     Document Type: Article

References (52)

1. Picchioni MM, Murray RM. Schizophrenia. BMJ 2007;335:91-95.
2. Simonsen C, Sundet K, Vaskinn A et al. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. Schizophr Bull 2011;37:73-83.
3. Van OJ, Rutten BP, Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull 2008;34:1066-1082.
4. Hoye A, Jacobsen BK, Hansen V. Increasing mortality in schizophrenia: are women at particular risk? A follow-up of 1111 patients admitted during 1980-2006 in Northern Norway. Schizophr Res 2011;132:228-232.
5. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45:21-28.
6. Fan Z, Wu Y, Shen J, Ji T, Zhan R. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res 2013;47:1549-1556.
7. Birkenaes AB, Opjordsmoen S, Brunborg C et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry 2007;68:917-923.
8. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997;171:502-508.
9. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428.
10. Saari K, Jokelainen J, Veijola J et al. Serum lipids in schizophrenia and other functional psychoses: a general population northern Finland 1966 birth cohort survey. Acta Psychiatr Scand 2004;110:279-285.
11. Paton C, Esop R, Young C, Taylor D. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004;110:299-305.
12. Bushe C, Paton C. The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link? J Psychopharmacol 2005;19:76-83.
13. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119:4-14.
14. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009;119:171-179.
15. Assies J, Mocking RJ, Lok A, Ruhe HG, Pouwer F, Schene AH. Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity. Acta Psychiatr Scand 2014;230:163-180.
16. Tsaluchidu S, Cocchi M, Tonello L, Puri BK. Fatty acids and oxidative stress in psychiatric disorders. BMC Psychiatry 2008;8(Suppl 1):S5.
17. McCarthy MJ. Oxidative stress: a link between cardiovascular disease and psychiatric illness? Acta Psychiatr Scand 2014;130:161-162.
18. Kaddurah-Daouk R, McEvoy J, Baillie R et al. Impaired plasmalogens in patients with schizophrenia. Psychiatry Res 2012;198:347-352.
19. Schwarz E, Prabakaran S, Whitfield P et al. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 2008;7:4266-4277.
20. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry 2004;47(Suppl):S76-S79.
21. Saari K, Lindeman S, Koponen H, Jokelainen J, Isohanni M. Higher serum triglyceride levels in early-onset schizophrenia. Am J Psychiatry 2004;161:176.
22. Huang TL, Chen JF. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res 2005;80:55-59.
23. Chen SF, Hu TM, Lan TH, Chiu HJ, Sheen LY, Loh EW. Severity of psychosis syndrome and change of metabolic abnormality in chronic schizophrenia patients: severe negative syndrome may be related to a distinct lipid pathophysiology. Eur Psychiatry 2014;29:167-171.
24. Vik-Mo AO, Birkenaes AB, Ferno J, Jonsdottir H, Andreassen OA, Steen VM. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int J Neuropsychopharmacol 2008;11:679-684.
25. Krakowski M, Czobor P. Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol. Schizophr Res 2011;130:27-33.
26. Lally J, Gallagher A, Bainbridge E, Avalos G, Ahmed M, McDonald C. Increases in triglyceride levels are associated with clinical response to clozapine treatment. J Psychopharmacol 2013;27:401-403.
27. Procyshyn RM, Wasan KM, Thornton AE et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci 2007;32:331-338.
28. Bhatnagar D, Soran H, Durrington PN. Hypercholesterolaemia and its management. BMJ 2008;337:a993.
29. Vik-Mo AO, Ferno J, Skrede S, Steen VM. Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells. BMC Pharmacol 2009;9:10.
30. Mahadik SP, Evans DR. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr Clin North Am 2003;26:85-102.
31. Bentsen H, Solberg DK, Refsum H et al. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol Psychiatry 2011;70:97-105.
32. Hoen WP, Lijmer JG, Duran M, Wanders RJ, van Beveren NJ, De HL. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res 2013;207:1-12.
33. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002;58:1-10.
34. McEvoy J, Baillie RA, Zhu H et al. Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS ONE 2013;8:e68717.
35. Sumiyoshi T, Higuchi Y, Matsui M et al. Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia. Psychiatry Res 2011;186:23-27.
36. Bentsen H, Solberg DK, Refsum H, Bohmer T. Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells. Prostaglandins Leukot Essent Fatty Acids 2012;87:35-41.
37. van der Gaag M, Hoffman T, Remijsen M et al. The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res 2006;85:280-287.
38. Pedersen G, Hagtvet KA, Karterud S. Generalizability studies of the Global Assessment of Functioning-Split version. Compr Psychiatry 2007;48:88-94.
39. Bai YM, Lin CC, Chen JY, Lin CY, Su TP, Chou P. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006;163:1276-1279.
40. Czobor P, Volavka J, Sheitman B et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002;22:244-251.
41. Venkatasubramanian G, Rao NP, Arasappa R, Kalmady SV, Gangadhar BN. A longitudinal study of relation between side-effects and clinical improvement in schizophrenia: is there a neuro-metabolic threshold for second generation antipsychotics? Clin Psychopharmacol Neurosci 2013;11:24-27.
42. Sethom MM, Fares S, Bouaziz N et al. Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2010;83:131-136.
43. Wu JQ, Kosten TR, Zhang XY. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013;46:200-206.
44. Saari K, Koponen H, Laitinen J et al. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study. J Clin Psychiatry 2004;65:547-550.
45. de Hert M, van Winkel R, van Eyck D et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2006;2:14.
46. Wu X, Huang Z, Wu R et al. The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls. Schizophr Res 2013;150:157-162.
47. Tiihonen J, Lonnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620-627.
48. Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res 2013;47:197-207.
49. Andreassen OA, Djurovic S, Thompson WK et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet 2013;92:197-209.
50. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
51. Reddy RD, Keshavan MS, Yao JK. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull 2004;30:901-911.
52. Kaddurah-Daouk R, McEvoy J, Baillie RA et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007;12:934-945.